CRO Omnicare Clinical Research, based in King of Prussia, Penn., has re-branded the company under the name Theorem Clinical Research. The brand launch marks the final step in the CRO's separation from its former parent company in a deal that was finalized this spring.
Nautic Partners, a private equity firm based in Providence, R.I., acquired the CRO in April. The deal marked the official the separation of Omnicare Clinical Research from former parent company Omnicare.
It also, the company said, accomplished its most visible step in achieving its long-identified goal: to stand on its own and deliver results the way that clients need.
Under its new name, Theorem Clinical Research will continue to provide clinical trial management, with a continued focus on its core early phase, phase II/III and late phase, and its specialized business units in pharmaceutics, medical device and technical services (biometrics and clinical data management).
"This is 25 years in the making," said Dr. James Pusey, president and CEO of Theorem Clinical Research. “We are now in the driver's seat of our own company.”
Over the last five years the company has completed over 1,500 studies worldwide with more than 337,000 participating patients.